Partnerships
Partnering with us
Our proprietary precision biomarkers from hair analysis are revolutionizing clinical trials.
Biomarkers are the key to clinical success. For decades, clinical trials for CNS and other conditions have failed. Some came up short because the drug was tested against the wrong patient population. Others failed because of ill-defined and/or subjective endpoints.
By analyzing a single strand of hair, our platform can provide critical information about a participant’s health, whether they have complied with the therapeutic regimen, how effectively their body metabolizes the drug and other important information.
- Autism spectrum disorder
- Lead poisoning
- The microbiome
Advantages
What does the LinusBio platform provide?
LinusBio’s technology is built on a decade of academic research conducted by co-founder and CEO Manish Arora, Ph.D., Vice Chairman of the Department of Environmental Medicine and Climate Science at the Icahn School of Medicine at Mount Sinai. The initial work was conducted in teeth and has since been reapplied to hair.
Molecular data to deliver objective endpoints and help companies better understand whether their therapy succeeded or failed.
A fast and easy screening tool to enroll the most appropriate clinical trial cohorts.
Longitudinal environmental exposure data that would otherwise require hundreds of blood tests over a period of years.
Our Platform
LinusBio’s platform delivers deep molecular phenotyping through a single strand of hair. Patented robotics process samples, while proprietary laser technology extracts molecules at precise time points. Machine learning algorithms then map and analyze biological responses to environmental exposures, identifying molecular signatures that characterize disorders with unprecedented precision.
Pipeline
LinusBio is pioneering advanced diagnostics for complex central nervous system disorders.
Pipeline
LinusBio is pioneering advanced diagnostics for complex central nervous system disorders.
LinusBio is advancing next-generation diagnostics for complex central nervous system disorders, including Autism Spectrum Disorder (ASD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Attention Deficit Hyperactive Disorder (ADHD), and Psychosis/Schizophrenia.
By leveraging cutting-edge technology, we decode molecular signatures tied to these conditions, enabling earlier detection, precise patient stratification, and personalized therapeutic strategies. Our innovations aim to replace subjective assessments with objective, data-driven insights, transforming how these disorders are diagnosed and managed.
Learn how to leverage our platform for your clinical trials
